Share this article
Share this article
HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMEND™ annuloplasty ring. The transseptal AMEND procedure was performed at the Schulich Heart Centre at Sunnybrook Health Sciences Centre in Toronto, under the Health Canada Special Access Program.
Valcare s AMEND mitral repair annuloplasty ring (PRNewsfoto/Valcare Medical Ltd.)
Valcare s AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities. AMEND is designed to provide the clinical standard-of-care surgical treatment via safer and easier catheter-based procedures. The AMEND platform also serves as infrastructure for Valcare s mitral replacement system and tricuspid repair solution.
Valcare Medical Announces First-in-Human Transseptal Implant of the AMEND Annuloplasty Ring for Mitral Valve Repair
HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMEND annuloplasty ring. The transseptal AMEND procedure was performed at the Schulich Heart Centre at Sunnybrook Health Sciences Centre in Toronto, under the Health Canada Special Access Program.
Valcare s AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities. AMEND is designed to provide the clinical standard-of-care surgical treatment via safer and easier catheter-based procedures. The AMEND platform also serves as infrastructure for Valcare s mitral replacement system and tricuspid repair solution.